本帖最后由 老马 于 2013-3-13 13:43 编辑
9 u) F! q. K6 F6 q" i9 ], k4 Q# `
# c" _! d4 z" A0 \健择（吉西他滨）+顺铂+阿瓦斯汀
& Q6 q$ Y% t5 Z* p6 r- C Gemzar +Cisplatin + Avastin
4 c6 V% Y- G5 I; [& B* hhttp://annonc.oxfordjournals.org/content/21/9/1804.full% G0 Q0 Q1 K' B1 a, e
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 5 Z; J1 G. U; ~9 ~6 k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% s" N( K" C$ A; e! VResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ' @ c" q4 Q1 q6 J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 846)
3 a D& J5 M8 u3 w5 w
华为网盘附件：
+ N- Y1 X0 `8 U, B【华为网盘】ava.JPG. o# R2 F' r& {, Z
|
显身卡
